Clinical Trial Update: BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 randomized trial of volasertib (BI-6727) in ovarian cancer has completed and posted results. The study investigated volasertib in ovarian neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Volasertib (Volasertib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Ovarian Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2015-08-13